DMD Therapeutics, a Seattle, WA-based biotech startup, received $400k in funding.
The company intends to use the funds to move DMD-813 into drug development for the treatment of Duchenne Muscular Dystrophy.
Co-founded in 2016 by Ron Berenson, MD, and Carlo Rago, PhD, Chief Scientific Officer, DMD Therapeutics is developing proprietary therapeutics for Duchenne muscular dystrophy (DMD)*.
* DMD is an X-linked genetic disorder, which occurs in approximately 1 in 3,800 male births with an incidence rate that does not significantly vary around the world. In rare cases, females are affected. There are approximately 15,000 and 32,000 individuals living with this disease in the US and Europe, respectively. It is a severe disorder characterized by progressive deterioration of muscle function, which becomes evident in children at approximately 3-5 years old. Patients become wheelchair bound in the early second decade of life. In their late teens and early twenties, most patients develop cardiac and pulmonary failure leading to death in their late twenties to early thirties.